Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

(2023) Dariusz Rozkiewicz et al.   MOLECULES

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome

(2022) Raphaele Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors

(2022) Bin Ma et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A comprehensive overview of living with Sjögren’s: results of a National Sjögren’s Foundation survey

(2022) Sara S. McCoy et al.   CLINICAL RHEUMATOLOGY

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

(2022) Elizabeth Price et al.   RHEUMATOLOGY

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

(2022) Marcus Maurer et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

(2022) Jing He et al.   JAMA Network Open

Human IgA-Expressing Bone Marrow Plasma Cells Characteristically Upregulate Programmed Cell Death Protein-1 Upon B Cell Receptor Stimulation

(2021) Annika Wiedemann et al.   Frontiers in Immunology

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

(2021) H. Yesid Estupiñán et al.   Frontiers in Cell and Developmental Biology

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

(2021) Martin Kaul et al.   CTS-Clinical and Translational Science

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

(2021) Stefan F. H. Neys et al.   Frontiers in Cell and Developmental Biology

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

(2021) Simon J Bowman et al.   LANCET

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

(2021) Garth E. Ringheim et al.   Frontiers in Immunology

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

(2020) Daniela Angst et al.   JOURNAL OF MEDICINAL CHEMISTRY

Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sjögren's syndrome reveals a pathogenic signature

(2020) Gwenny M. Verstappen et al.   JOURNAL OF AUTOIMMUNITY

A Fast and Clean BTK Inhibitor

(2020) Ronen Gabizon et al.   JOURNAL OF MEDICINAL CHEMISTRY

Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

(2020) Renaud Felten et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for caries development in Primary Sjogren's Syndrome

(2019) Nicola Berman et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Primary Sjögren’s Syndrome

(2018) Xavier Mariette et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages

(2017) Lingyan Ping et al.   Oncotarget

Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease

(2017) Odilia B. J. Corneth et al.   Arthritis & Rheumatology

Fc Receptor–like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue–like Memory B Cells

(2016) Huifang Li et al.   JOURNAL OF IMMUNOLOGY

2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts

(2016) Caroline H. Shiboski et al.   Arthritis & Rheumatology

Sjögren syndrome

(2016) Pilar Brito-Zerón et al.   Nature Reviews Disease Primers

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

(2015) Yetrib Hathout et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study

(2015) Salvatore De Vita et al.   RHEUMATOLOGY

Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis

(2014) Baodong Qin et al.   ANNALS OF THE RHEUMATIC DISEASES

The epidemiology of Sjögren’s syndrome

(2014) Anupama Shahane et al.   Clinical Epidemiology

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Clock Genes Show Circadian Rhythms in Salivary Glands

(2012) L. Zheng et al.   JOURNAL OF DENTAL RESEARCH